Influenza A virus (H1N1) pdm09 neuraminidase and internal viral proteins (A(H1N1)pdm09 NA/Internal Proteins)

The Influenza A virus (H1N1) pdm09 neuraminidase (NA) and internal viral proteins, including nucleoprotein (NP) and matrix protein (M1), represent a complex of antigenic targets derived from the 2009 pandemic H1N1 strain. Neuraminidase is a surface glycoprotein with enzymatic activity essential for viral egress, as it cleaves sialic acid residues to release progeny virions; this activity is the primary target for inhibitors such as oseltamivir and zanamivir (Gubareva et al., 2000). Internal proteins like NP and M1 are highly conserved across influenza A subtypes and are critical for inducing cross-reactive T-cell mediated immunity, which can mitigate disease severity even when surface antigens drift (Sridhar et al., 2013). These proteins are utilized in various vaccine platforms to elicit a broad immune response. While NA inhibitors remain a cornerstone of influenza therapy, the emergence of resistance mutations and the need for broad-spectrum protection drive the inclusion of conserved internal proteins in next-generation vaccine strategies. Notable safety concerns include the rare association of specific 2009 H1N1 vaccines with narcolepsy and the ongoing challenge of antigenic drift (Sahlström et al., 2012).

Other names

H1N1pdm09 antigens2009 pandemic H1N1 antigensA/California/04/2009-like antigensApdm09 neuraminidasepdm09 internal proteinsInfluenza A pandemic 2009 antigens

Neuraminidase inhibitors (e.g., oseltamivir) competitively inhibit the viral neuraminidase enzyme, preventing the cleavage of sialic acid and the release of progeny virions (Gubareva et al., 2000). As vaccine antigens, these proteins induce neutralizing antibodies against NA and activate cross-reactive T-cell responses against conserved internal proteins like NP and M1 (Sridhar et al., 2013).